Literature DB >> 7324176

Cardiomyopathy of doxorubicin in experimental animals, Factors affecting the severity, distribution and evolution of myocardial lesions.

E Solcia, L Ballerini, O Bellini, U Magrini, C Bertazzoli, G Tosana, L Sala, F Balconi, F Rallo.   

Abstract

Heart lesions induced in mice, rats, rabbits and dogs by Doxorubicin administered i.v. according to various schedules were studied by light and electron microscopy Vacuolization of myocardial cytoplasm due to distention of the sarcoplasmic reticulum, the T-tubule system and the Golgi vesicles was one of the most common findings. Myocytolysis, clumping and loss of fibrils, fragmentation of sarcomeres, swelling of mitochondria and an increase in lysosomes and residual bodies were also observed. The severity of the cardiomyopathy, quantitatively evaluated by a score system, proved to be dose-dependent. Cardiomyopathy was more severe when the treatment was given in a short period by administration of high doses than when the same cumulative dose was administered as low doses repeated for a long period. The left atrium was more severely affected than the ventricles when high doses were given, whereas it was less affected in animals given low doses. The cardiomyopathy was less severe in animals receiving the same dose in a high volume of solvent and during a long perfusion time. Threshold doses were needed both to induce the cardiomyopathy and to establish it as a progressive disease.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7324176     DOI: 10.1177/030089168106700512

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  14 in total

Review 1.  Cardiotoxicity of doxorubicin and other anthracycline derivatives.

Authors:  D Jain
Journal:  J Nucl Cardiol       Date:  2000 Jan-Feb       Impact factor: 5.952

2.  Doxorubicin Blocks Cardiomyocyte Autophagic Flux by Inhibiting Lysosome Acidification.

Authors:  Dan L Li; Zhao V Wang; Guanqiao Ding; Wei Tan; Xiang Luo; Alfredo Criollo; Min Xie; Nan Jiang; Herman May; Viktoriia Kyrychenko; Jay W Schneider; Thomas G Gillette; Joseph A Hill
Journal:  Circulation       Date:  2016-03-16       Impact factor: 29.690

Review 3.  Myocardial diseases of animals.

Authors:  J F Van Vleet; V J Ferrans
Journal:  Am J Pathol       Date:  1986-07       Impact factor: 4.307

4.  Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit.

Authors:  B J Cusack; S P Young; J Driskell; R D Olson
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Cardiac matrix alterations induced by adriamycin.

Authors:  J B Caulfield; V Bittner
Journal:  Am J Pathol       Date:  1988-11       Impact factor: 4.307

6.  Effect of metoprolol on activity of beta-adrenoceptor coupled to guanine nucleotide binding regulatory proteins in adriamycin-induced cardiotoxicity.

Authors:  L X Fu; C H Bergh; J Hoebeke; Q M Liang; K G Sjögren; F Waagstein; A Hjalmarson
Journal:  Basic Res Cardiol       Date:  1991 Mar-Apr       Impact factor: 17.165

7.  Doxorubicin cardiotoxicity is associated with alterations of plasma levels of atrial natriuretic factor.

Authors:  N Bernardini; C Agen; S Favilla; R Danesi; M Del Tacca
Journal:  J Endocrinol Invest       Date:  1992-02       Impact factor: 4.256

8.  Lysosomal alterations in heart and liver of mice treated with doxorubicin.

Authors:  N Gebbia; G Leto; M Gagliano; F M Tumminello; L Rausa
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

9.  Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in a chronic rabbit model.

Authors:  D A Dodd; J B Atkinson; R D Olson; S Buck; B J Cusack; S Fleischer; R J Boucek
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

Review 10.  Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation.

Authors:  Atiar M Rahman; Syed Wamique Yusuf; Michael S Ewer
Journal:  Int J Nanomedicine       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.